Rob Kessels

Assistant Professor

Strategic program(s):

Biography

I am clinical trial methodology researcher and biostatistician working at the Clinical Trial Methodology and Statistical Consultation group within the Department of Data Science and Biostatistics at the Julius Center. My research is focused on developing and implementing innovative (early-phase) adaptive clinical trials within Oncode Accelerator. I am also involved in the design, methodology, and analysis of (oncology) clinical trials.

Before joining the UMC Utrecht, I worked as a statistician at the Antoni van Leeuwenhoek hospital/Netherlands Cancer Institute focusing on design and analysis of oncology clinical trials and I was involved in the Dutch Oncology Research Platform (DORP), an initiative to support investigator initiated clinical research.

I hold a PhD degree in Statistics from Utrecht University (2022) and a MSc degree in Methodology and Statistics for the Behavioural, Biomedical and Social Sciences from Utrecht University (2014).

Strategic program(s):

Contact

rkessel2@umcutrecht.nl

Pure profile

Research groups

Clinical trial methodology & statistical consultation

Research aim

We develop, evaluate, and apply innovative clinical trial designs and sound statistical methodology to efficiently obtain high-quality evidence on healthcare interventions, ultimately optimizing patient outcomes

Go to group

Recent publications

All publications

PrimerX: A Bayesian Multistage Cohort Embedded Randomised Trial to Evaluate the Role of Deferred Local Therapy of the Primary Tumour in Combination with Immune Checkpoint Inhibitor–based First-line Therapy in Metastatic Renal Cell Carcinoma Patients Orlane Figaroa, Patricia Zondervan, Rob Kessels, Johannes Berkhof, Maureen Aarts, Paul Hamberg, Maartje Los, Djura Piersma, Bart Rikhof, Britt Suelmann, Metin Tascilar, Astrid van der Veldt, Paul Verhagen, Hans Westgeest, Hilin Yildirim, Axel Bex, Adriaan Bins
European Urology Open Science, 2024, vol. 70, p.28-35

Cost-effectiveness of treating advanced melanoma with tumor-infiltrating lymphocytes based on an international randomized phase 3 clinical trial Renske M T Ten Ham, Maartje W Rohaan, Inge Jedema, Rob Kessels, Wim Stegeman, Walter Scheepmaker, Bastiaan Nuijen, Cynthia Nijenhuis, Melanie Lindenberg, Troels Holz Borch, Tine Monberg, Marco Donia, Inge Marie Svane, Wim van Harten, John Haanen, Valesca P Retel
Journal for ImmunoTherapy of Cancer, 2024, vol. 12, p.1-24

MRI-guided optimisation of neoadjuvant chemotherapy duration in stage II-III HER2-positive breast cancer (TRAIN-3) Anna van der Voort, Fleur M Louis, Mette S van Ramshorst, Rob Kessels, Ingrid A Mandjes, Inge Kemper, Mariette J Agterof, Wim A van der Steeg, Joan B Heijns, Marlies L van Bekkum, Ester J Siemerink, Philomeen M Kuijer, Astrid Scholten, Jelle Wesseling, Marie-Jeanne T F D Vrancken Peeters, Ritse M Mann, Gabe S Sonke,
LANCET ONCOLOGY, 2024, vol. 25, p.603-613

Phase I feasibility study of Olaparib in combination with loco-regional radiotherapy in head and neck squamous cell carcinoma Arash Navran, Abrahim Al-Mamgani, Hester Elzinga, Rob Kessels, Conchita Vens, Margot Tesselaar, Michiel van den Brekel, Rosemarie de Haan, Baukelien van Triest, Marcel Verheij
Clinical and translational radiation oncology, 2024, vol. 44

Tailored guidance to apply the Estimand framework to Trials within Cohorts (TwiCs) studies R. Gal, R. Kessels, K. Luijken, L. A. Daamen, D. R. Mink van der Molen, S. A.M. Gernaat, A. M. May, H. M. Verkooijen, P. M. van de Ven
Global Epidemiology, 2024, vol. 8

The Trial within Cohorts (TwiCs) study design in oncology Rob Kessels, Anne M May, Miriam Koopman, Kit C B Roes
BMC Medical Research Methodology, 2023, vol. 23